ESC Clinical Practice Guidelines for the Management of Atrial Fibrillation:
KEYWORDS: blood, heart, patients, risk, healthcare, receive, rhythm, clots, thinners, blood clots, blood thinners, stroke, factors, team, treatment

of the blood to clot. They are highly effective in preventing strokes in patients with AF and are recommended for all patients who have risk factors for developing blood clots. Choice of blood thinner Most patients with AF should receive a direct oral anticoagulant (or DOAC), which includes the drugs, apixaban, dabigatran, edoxaban or rivaroxaban. The specific choice will often depend on local factors. DOACs require only occasional blood tests for kidney and liver function (around every 6 months). Drugs like warfarin, phenprocoumon, acenocoumarol and fluindione may be prescribed to certain patients, such as those with mechanical heart valves, severe forms of mitral valve disease, severe kidney disease and in pregnancy. These drugs require frequent blood tests (the international normalised ratio or INR) to make sure the correct dose is being received. Your healthcare team may suggest you switch from warfarin to the newer DOAC tablets for a number of reasons: • Your choice, to benefit from a lower risk of bleeding • To avoid interactions with foods and other drugs that are more common with warfarin • When there is difficulty keeping to your INR target • If you have a high risk of bleeding in the brain or
